|
Sustained Drug Delivery for Posterior Uveitis
The main line of treatment for non-infectious posterior uveitis involves systemic or periocular steroids. They offer excellent inflammation control but could lead to side effects such as diabetes mellitus, hypertension, weakening of bones,
myopathy, mood changes and weight gain. Therefore, steroid sparing agents (or immunomodulatory agents) are prescribed to reduce the total dose and administration period of systemic steroids.
LVPEI is a part of the trial process for a new drug delivery system wherein a tiny device with a minuscule amount of steroid is surgically inserted into the vitreous cavity of the eye.
|
